Australian expert rejects criticism of oncology trials bias

An Australian expert has rejected claims that oncology clinical trials are increasingly compromised by use of surrogate outcomes and industry funding. A new review has noted a swing in recent years to greater use of surrogate end points along with a “massive shift” to pharmaceutical industry sponsorship. The study of trends in randomised controlled trials ...

Already a member?

Login to keep reading.

© 2022 the limbic